Analyst Price Target is $37.00
▲ +135.52% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Aerovate Therapeutics in the last 3 months. The average price target is $37.00, with a high forecast of $48.00 and a low forecast of $27.00. The average price target represents a 135.52% upside from the last price of $15.71.
Current Consensus is
The current consensus among 3 polled investment analysts is to buy stock in Aerovate Therapeutics. This Buy consensus rating has held steady for over two years.
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.